12 completed, 8 terminated, 1 withdrawn. 18 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 11, Terminated 6, Withdrawn 1 |
| Phase 2 | 9 | Completed 5, Terminated 4 |
Follow Plexxikon: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD BRD4 Inhibitor PLX51107 - Acute Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease | Phase 1 / Phase 2 | Terminated | Hannah Choe, MD | 2 | 2022-04-19 | 2025-01-28 |
| A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) MEK162, Pexidartinib - Gastrointestinal Stromal Tumor (GIST) | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2017-04-15 | 2021-04-30 |
| Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers Pexidartinib, Durvalumab - Colorectal Cancer, Pancreatic Cancer | Phase 1 | Completed | Centre Leon Berard | 48 | 2016-06-01 | 2021-09-05 |
| A Study of PLX51107 in Advanced Malignancies PLX51107 - Solid Tumors, Acute Myeloid Leukemia | Phase 1 | Terminated | Plexxikon | 50 | 2016-03-01 | 2018-12-24 |
| A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor PLX73086 - Solid Tumors, Tenosynovial Giant Cell Tumor | Phase 1 | Terminated | Plexxikon | 11 | 2016-02-01 | 2018-08-02 |
| A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors PLX3397, Pembrolizumab - Melanoma, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 78 | 2015-07-02 | 2020-03-05 |
| CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors CGT9486, Pexidartinib, Sunitinib - Gastrointestinal Stromal Tumors | Phase 1 / Phase 2 | Completed | Cogent Biosciences, Inc. | 51 | 2015-03-06 | 2025-02-14 |
| A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma PLX3397, vemurafenib - V600-mutated BRAF Unresectable Melanoma, V600-mutated BRAF Metastatic Melanoma | Phase 1 | Terminated | Daiichi Sankyo | 13 | 2013-11-05 | 2020-05-28 |
| Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors PLX7486 TsOH - Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations | Phase 1 | Terminated | Plexxikon | 59 | 2013-08-01 | 2018-08-02 |
| A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma PLX3397, Radiation Therapy, Temozolomide - Patients With Newly Diagnosed Glioblastoma | Phase 1 / Phase 2 | Completed | Daiichi Sankyo | 65 | 2013-07-18 | 2020-06-30 |
| Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer PLX3397, Eribulin - Metastatic Breast Cancer | Phase 1 / Phase 2 | Completed | Hope Rugo, MD | 67 | 2012-07-12 | 2020-07-17 |
| Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC) PLX3397 - Prostate Cancer | Phase 2 | Terminated | Daiichi Sankyo | 6 | 2012-05-25 | 2020-03-04 |
| Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors PLX3397, Paclitaxel - Solid Tumors | Phase 1 | Completed | Daiichi Sankyo | 74 | 2012-05-01 | 2020-07-16 |
| A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma PLX3397 - Recurrent Glioblastoma | Phase 2 | Terminated | Daiichi Sankyo | 38 | 2011-12-03 | 2020-03-03 |
| Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) PLX3397 - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Daiichi Sankyo | 90 | 2011-11-21 | 2020-03-02 |
| Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate PLX5622, Placebo - Rheumatoid Arthritis | Phase 1 | Completed | Plexxikon | 26 | 2011-05-01 | 2012-04-12 |
| Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma PLX3397 - Hodgkin Lymphoma | Phase 2 | Completed | Daiichi Sankyo | 20 | 2011-03-03 | 2020-06-30 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers PLX5622, Placebo - Healthy | Phase 1 | Completed | Plexxikon | 32 | 2011-01-01 | 2015-03-30 |
| Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate PLX3397 - Rheumatoid Arthritis | Phase 1 | Withdrawn | Plexxikon | 2010-05-01 | 2015-03-17 | |
| Safety Study of PLX108-01 in Patients With Solid Tumors PLX3397 - Solid Tumor | Phase 1 | Completed | Daiichi Sankyo | 132 | 2009-10-01 | 2022-01-04 |
Showing 20 of 21. Sign in to see all of them.
Gastrointestinal Stromal Tumors (3) · Arthritis, Rheumatoid (2) · Colorectal Neoplasms (2) · Giant Cell Tumor of Tendon Sheath (2) · Glioblastoma (2) · Leukemia, Myeloid, Acute (2) · Melanoma (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Hodgkin Disease (1) · Joint Diseases (1) · Lymphoma, Non-Hodgkin (1)
pexidartinib (14) · PLX51107 (2) · PLX5622 (2) · Vemurafenib (2) · Paclitaxel (1) · Radiotherapy (1) · Sunitinib (1) · Temozolomide (1) · binimetinib (1) · durvalumab (1) · eribulin (1) · pembrolizumab (1)
United States (20) · France (2) · Australia (1) · Germany (1)
Alexander Perl, MD (1) · Catherine Smith, MD (1) · Eunice Wang, MD (1) · Gail Roboz, MD (1) · Gregory Haugen, MD (1) · Hannah Choe, MD (1) · Henry Hsu, MD (1) · Hope S. Rugo, MD (1) · Jessica Sachs, MD (1) · John Pagel, MD, PhD (1) · Mark Levis, MD, PhD (1) · Olga Frankfurt, MD (1)
PMID 20818844, PMID 22256804, PMID 24101040, PMID 24552317, PMID 25980594, PMID 26222558, PMID 26460303, PMID 31213500, PMID 32330242, PMID 33289960, PMID 34236401, PMID 34716196, PMID 38266104, PMID 38775157
2015 (1), R01CA252469 (1)